InvestorsHub Logo
Followers 8
Posts 117
Boards Moderated 0
Alias Born 02/17/2014

Re: elkonig post# 4122

Thursday, 08/27/2020 11:33:47 AM

Thursday, August 27, 2020 11:33:47 AM

Post# of 4261

Looks like a worthless shell at this point?
Last filings mentions a Licensing Agreement.
AS increased to 25 Billion
And, reverse stock split (never approved)?
See: 8-K 09-22-2017

https://sec.report/CIK/0001542335

ITEM 5.03 AMENDMENTS TO ARTICLES OF INCORPORATION OR BYLAWS; CHANGE IN FISCAL YEAR

On August 23, 2017, the majority of the shareholders of the Company voted to effectuate an increase in the authorized amount of common stock from 6,000,000,000 to 25,000,000,000. Additionally, the majority of the shareholders of the Company authorized the establishment of Preferred Series B Shares with an authorized amount of 1,000 shares at a par value of $0.0001 and 100,000,000 votes per share. The Board of Directors of the Company filed with the State of Delaware accordingly.

On September 20, 2017, the majority of the shareholders of the Company voted to effectuate a reverse stock split at an exchange ratio of 1 post-split share for 100 pre-split shares (1:100) up to 1 post-split share for 500 pre-split shares (1:500), at the Board of Director’s discretion. The Board of Directors of the Company determined that the exchange ratio should be 1 post-split share for 300 pre-split shares (1:300) and filed with the State of Delaware accordingly.

On September 22, 2017, the Board of Directors of the Company determined that with the Company’s recent changes in regards to the Licensing Agreement with Active Lab, as well as the future plans of the Company, a name change was warranted. The Board of Directors have authorized the filing with the State of Delaware to change its name to Arize Therapeutics, Inc. The Company will be filing for a symbol change.

CONTACT INFO

Richard Pucci
Active Lab, Chief Executive Officer
3651 Lindell Road, Suite D395
Las Vegas, NV 89103
(702) 318-7525
rfpucci@activelaboratoryinc.com

Ira Morris (BLKG)
Chief Executive Officer
50 Fountain Plaza, Suite 1400
Buffalo, NY 14202
(716) 961-3244
Email: ira.morris@sympatico.ca

FORM 8-K 09-22-2017
https://last10k.com/sec-filings/blkg/0001477932-17-004662.htm

PR August 09, 2017
https://www.einpresswire.com/article/397154516/black-stallion-executes-exclusive-licensing-and-distribution-with-active-lab-international
Join InvestorsHub

Join the InvestorsHub Community

Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.